


Attorney Docket No. 04271500 Application No. 10/823,435 GIROUX et al. Sheet 1 of 63



# Advantages

- US Patent issued 1995
- Fast encapsulation time -- milliseconds Minimal exposure to polymer solvent High encapsulation efficiency Good Yields
- Makes small microparticles <100 micron <10 micron

# Drugs Microencapsulated

- **Proteins**
- Peptides
- Small molecules
- Water-soluble drugs
- Hydrophobic drugs
- Drugs encapsulated in
- lactide/glycolide polymers

Figure 1

Attorney Docket No. 04271500 Application No. 10/823,435 GIROUX et al. Sheet 2 of 63




Figure 2



Figure 3

Attorney Docket No. 04271500 Application No. 10/823,435 GIROUX et al. Sheet 3 of 63




Figure 4

#### Attorney Docket No. 04271500 Application No. 10/823,435 GIROUX et al. Sheet 4 of 63

Conditions: Ambient

Material:	PX510	PX261	PX749	PX125	PX510 + 14% Paclitaxel
Hardness:	F	В	3B	4B	F

Conditions: 5 minutes in 37°C pH 7.4 Saline Buffer

Material:	PX510	PX261	PX749	PX125	PX510 + 14% Paclitaxel
Hardness:	F	В	9B	<9B	F

Hardness Rating:

2H-H-F-HB-B-2B-3B-4B-5B-6B-7B-8B-9B

Harder → Softer

Figure 5

## Attorney Docket No. 04271500 Application No. 10/823,435 GIROUX et al. Sheet 5 of 63

**Conditions: Ambient** 

Material:	PX510	PX261	PX749	PX125	PX510 + 14% Paclitaxel
Resistance					
To Cracking	< 3 mm	< 3 mm	< 3mm	< 3mm	<3mm

Conditions: 5 minutes in 37°C pH 7.4 Saline Buffer

Material:	PX510	PX261	PX749	PX125	PX510 + 14% Paclitaxel
Resistance					
To Cracking	< 3 mm	< 3 mm	< 3mm	< 3mm	< 3mm

Figure 6

#### Attorney Docket No. 04271500 Application No. 10/823,435 GIROUX et al. Sheet 6 of 63

**Conditions: Ambient** 

Material:	PX510	PX261	PX749	PX125	PX510 + 14% Paclitaxel
Class:	5B	5B	5B	4B	5B

Class Rating: 5B = 0% of coating removed from substrate

4B = Less than 5% of coating removed from substrate

Figure 7

Attorney Docket No. 04271500 Application No. 10/823,435 GIROUX et al. Sheet 7 of 63




Figure 8A

Attorney Docket No. 04271500 Application No. 10/823,435 GIROUX et al. Sheet 8 of 63




Figure 8B

#### Attorney Docket No. 04271500 Application No. 10/823,435 GIROUX et al. Sheet 9 of 63




Figure 9A

#### Attorney Docket No. 04271500 Application No. 10/823,435 GIROUX et al. Sheet 10 of 63




Figure 9B

# Attorney Docket No. 04271500 Application No. 10/823,435 GIROUX et al. Sheet 11 of 63

## **Formulation**

Property	PX510	PX721	PX261	PX749
T <sub>g</sub> (°C)	44	38	29	16
Tensile modulus (MPa)	2.0 (25 ℃ 5.1 (37 ℃	-		3.0 (25 °C)
Yield Strength (MPa)	Not observed		6.0 (25 °C)	
Ultimate Elongation (%)	1.5 (25 ℃ <b>350 (37 ℃</b>	•		500 (25 °C)

Figure 10

Attorney Docket No. 04271500 Application No. 10/823,435 GIROUX et al. Sheet 12 of 63




Figure 11

Attorney Docket No. 04271500 Application No. 10/823,435 GIROUX et al. Sheet 13 of 63

	E Beam (3 MRad)		γ (25-35 KGys)				
Property	PX510	PX721	PX261	PX510	PX721	PX261	
MW	-26%	-39%	-26%	-14%	N/C	N/C	
Hardness	-2 units	N/C	-1 unit	N/C	-3 units	-2 units	
Flexibility	N/C	N/C	N/C	N/C	N/C	N/C	
Adhesion	N/C	N/C	-1 unit	N/C	N/C	N/C	

N/C: no change

Figure 12

Attorney Docket No. 04271500 Application No. 10/823,435 GIROUX et al. Sheet 14 of 63




Figure 13A

Attorney Docket No. 04271500 Application No. 10/823,435 GIROUX et al. Sheet 15 of 63




Figure 13B

PX242 20-53 Coated Coupon Diflunisal Elution




Figure 14

# PX242 20-53 Coated Coupon Diflunisal Elution




Figure 15

Attorney Docket No. 04271500 Application No. 10/823,435 GIROUX et al. Sheet 18 of 63

Erosion of PolyAspirin I & II Generation of NSAID into 37 °C pH 7.4 PBS from ~5 μm-thick Coatings on 316L SS Plates





Figure 16

#### Attorney Docket No. 04271500 Application No. 10/823,435 GIROUX et al. Sheet 19 of 63

# Erosion Profile for PolyAspirin I



HPLC Retention Time (min)

Figure 17

#### Attorney Docket No. 04271500 Application No. 10/823,435 GIROUX et al. Sheet 20 of 63

Erosion Profile for PolyAspirin II

Diflunisal elutes @ 7.1 min Linker-substituted Diflunisal elutes @ 9.0 min Bis(diflunisal)-linker elutes @ 12 min




Figure 18

Attorney Docket No. 04271500 Application No. 10/823,435 GIROUX et al. Sheet 21 of 63

## Effect of MW on Erosion

# Generation of Diflunisal from PolyAspirin II into 37 °C Serum from Coatings on 316L SS Plates




Figure 19

#### Attorney Docket No. 04271500 Application No. 10/823,435 GIROUX et al. Sheet 22 of 63

# Tuning Mechanical Properties




Figure 20

## Attorney Docket No. 04271500 Application No. 10/823,435 GIROUX et al. Sheet 23 of 63

# Thermoanalysis of PolyAspirin™

PolyAspirin I		PolyAspirin II			
Property	PX261	PX657			
	$Mw \sim 20K$	$M_{\rm w} \sim 33K$	$M_{\rm w} \sim 100K$		
$T_g$ (°C)	29	36	44		
Ultimate Stress (kPa)	1700 (25°C) >2000 (37°C)	>2800 (25°C)	>2600 (25°C)		
Ultimate Elongation (%)	>500 (25°C) >500 (37°C)	>4 (25°C)	>500 (25°C)		
Toughness (kPa)	>3900 (25°C) >4400 (37°C)	>560 (25°C)	>4000 (25°C)		

Figure 21

# Attorney Docket No. 04271500 Application No. 10/823,435 GIROUX et al. Sheet 24 of 63

# Properties of PolyAspirin $^{TM}$ Coatings

	PolyAspirin I	PolyAspirin II		
	PX261	PX	<b>K</b> 657	
Test	Mw ~ 20K	Mw ~ 33K	Mw ~ 100K	
Hardness				
Ambient	В	F	3H	
5 min in PBS, 37 °C	В	2B	- B	
1 hr in PBS, 37 °C	-	8B	4B	
Flexibility				
Ambient	<3 mm	<3 mm	<3 mm	
5 min in PBS, 37 °C	<3 mm	<3 mm	<3 mm	
1 hr in PBS, 37 °C	-	<3 mm	<3 mm	
Adhesion				
Ambient	5B	5B	5B	

Figure 22

## Attorney Docket No. 04271500 Application No. 10/823,435 GIROUX et al. Sheet 25 of 63

# PolyAspirin Coatings with Admixtures


Test	PolyAspirin II (PX657)			
	No Admixture	20% Paclitaxel Admixed		
<u>Hardness</u>		_		
Ambient	F	F		
5 min in PBS, 37 °C	2B	F		
1 hr in PBS, 37 °C	8B	6B		
Flexibility				
Ambient	<3 mm	<3 mm		
5 min in PBS, 37 °C	<3 mm	<3 mm		
1 hr in PBS, 37 °C	<3 mm	<3 mm		
Adhesion				
Ambient	5B	5B		

Figure 23

## Attorney Docket No. 04271500 Application No. 10/823,435 GIROUX et al. Sheet 26 of 63

#### Erosion of PolyAspirin I & II

Diflunisal Generation & Paclitaxel Release into 37 °C Serum from  $\sim$ 5  $\mu$ m-thick Coatings on 316L SS Plates



→ Diflunisal (No Admix) → Diflunisal (20 wt% Paclitaxel) → Paclitaxel

Figure 24

#### Attorney Docket No. 04271500 Application No. 10/823,435 GIROUX et al. Sheet 27 of 63

#### Erosion of Sterilized PolyAspirin II

Generation of Diflunisal into 37 °C Serum from  $\sim$ 5  $\mu$ m-thick Coatings on 316L SS Plates




Figure 25

# Attorney Docket No. 04271500 Application No. 10/823,435 GIROUX et al. Sheet 28 of 63

# γ Irradiation (25-35 Kgys)

N/C: no change	PolyAspirin I	PolyAspirin II	
Property	$PX261$ $M_{\rm w} \sim 20K$	$PX657$ $M_{\rm w} \sim 100K$	
MW	N/C	-50%	
Hardness	-2 units	-3 units	٠
Flexibility	N/C	-	
Adhesion	N/C	-	

Figure 26

# Attorney Docket No. 04271500 Application No. 10/823,435 GIROUX et al. Sheet 29 of 63

## E Beam (3-4.5 MRad)

•Property	•PX261 •M <sub>w</sub> ~ 20 K	${}^{\bullet}M_{\rm w} \sim 33K$	${}^{\bullet}M_{\rm w} \sim 80{\rm K}$
•MW	•-26%	•+5%	•-30%
•Hardness	• 1 unit • PolyAspirin I	•+2 units •PolyAspirin II	•N/C
•Flexibility	•N/C	•PX657	•N/C
<ul><li>Adhesion</li></ul>	•-1 unit	•_	•-

Figure 27

Attorney Docket No. 04271500 Application No. 10/823,435 GIROUX et al. Sheet 30 of 63

#### **Kinetics of NSAID Generation**






Figure 28

# Attorney Docket No. 04271500 Application No. 10/823,435 GIROUX et al. Sheet 31 of 63



# Attorney Docket No. 04271500 Application No. 10/823,435 GIROUX et al. Sheet 32 of 63



# Attorney Docket No. 04271500 Application No. 10/823,435 GIROUX et al. Sheet 33 of 63






Figure 35










Figure 36


Attorney Docket No. 04271500 Application No. 10/823,435 GIROUX et al. Sheet 34 of 63



# Attorney Docket No: 04271500 Application No. 10/823,435 GIROUX et al. Sheet 35 of 63



Attorney Docket No. 04271500 Application No. 10/823,435 GIROUX et al. Sheet 36 of 63



#### Attorney Docket No. 04271500 Application No. 10/823,435 GIROUX et al. Sheet 37 of 63

## uncrimped/unexpanded




Figure 44

#### Attorney Docket No. 04271500 Application No. 10/823,435 GIROUX et al. Sheet 38 of 63

## uncrimped/unexpanded




Figure 45

#### Attorney Docket No. 04271500 Application No. 10/823,435 GIROUX et al. Sheet 39 of 63

## Uncrimped/unexpanded




Figure 46

Attorney Docket No. 04271500 Application No. 10/823,435 GIROUX et al. Sheet 40 of 63




Figure 47

Attorney Docket No. 04271500 Application No. 10/823,435 GIROUX et al. Sheet 41 of 63



Figure 48

### Attorney Docket No. 04271500 Application No. 10/823,435 GIROUX et al. Sheet 42 of 63




Figure 49

#### Attorney Docket No. 04271500 Application No. 10/823,435 GIROUX et al. Sheet 43 of 63




Figure 50

## Attorney Docket No. 04271500 Application No. 10/823,435 GIROUX et al. Sheet 44 of 63

Figure 51

Attorney Docket No. 04271500 Application No. 10/823,435 GIROUX et al. Sheet 45 of 63





Figure 52

#### Attorney Docket No. 04271500 Application No. 10/823,435 GIROUX et al. Sheet 46 of 63



PolySAA Closed: Ambient
PolyDF Open: Soaked 5 min in 37 °C PBS

Figure 53

Attorney Docket No. 04271500 Application No. 10/823,435 GIROUX et al. Sheet 47 of 63




Figure 54

Attorney Docket No. 04271500 Application No. 10/823,435 GIROUX et al. Sheet 48 of 63




Figure 55




Figure 56

# Attorney Docket No. 04271500 Application No. 10/823,435 GIROUX et al. Sheet 50 of 63




Figure 57

Attorney Docket No. 04271500 Application No. 10/823,435 GIROUX et al. Sheet 51 of 63




Figure 58




Figure 59

#### Attorney Docket No. 04271500 Application No. 10/823,435 GIROUX et al. Sheet 53 of 63




Figure 60

Attorney Docket No. 04271500 Application No. 10/823,435 GIROUX et al. Sheet 54 of 63




Figure 61

Attorney Docket No. 04271500 Application No. 10/823,435 GIROUX et al. Sheet 55 of 63




Figure 62

Attorney Docket No. 04271500
Application No. 10/823,435
GIROUX et al.
Sheet 56 of 63




Figure 63

Attorney Docket No. 04271500 Application No. 10/823,435 GIROUX et al. Sheet 57 of 63




Figure 64

Attorney Docket No. 04271500 Application No. 10/823,435 GIROUX et al. Sheet 58 of 63




Figure 65

## Attorney Docket No. 04271500 Application No. 10/823,435 GIROUX et al. Sheet 59 of 63




Figure 66

#### Attorney Docket No. 04271500 Application No. 10/823,435 GIROUX et al. Sheet 60 of 63




Figure 67

## Attorney Docket No. 04271500 Application No. 10/823,435 GIROUX et al. Sheet 61 of 63




Figure 68

Attorney Docket No. 04271500 Application No. 10/823,435 GIROUX et al. Sheet 62 of 63




Figure 69

Attorney Docket No. 04271500 Application No. 10/823,435 GIROUX et al. Sheet 63 of 63




Figure 70

# This Page is Inserted by IFW Indexing and Scanning Operations and is not part of the Official Record

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

BLACK BORDERS

IMAGE CUT OFF AT TOP, BOTTOM OR SIDES

FADED TEXT OR DRAWING

BLURRED OR ILLEGIBLE TEXT OR DRAWING

SKEWED/SLANTED IMAGES

COLOR OR BLACK AND WHITE PHOTOGRAPHS

GRAY SCALE DOCUMENTS

LINES OR MARKS ON ORIGINAL DOCUMENT

REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY

## IMAGES ARE BEST AVAILABLE COPY.

OTHER:

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.